Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?

Ragıp Ertaş; Kemal Özyurt; Sinem Yıldız; Yılmaz Ulaş; Abdullah Turasan; Atıl Avcı

Iranian Journal of Allergy, Asthma and Immunology (Jan 2016)

Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?

Ragıp Ertaş,
Kemal Özyurt,
Sinem Yıldız,
Yılmaz Ulaş,
Abdullah Turasan,
Atıl Avcı

Affiliations

Ragıp Ertaş: Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey
Kemal Özyurt: Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey
Sinem Yıldız: Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey
Yılmaz Ulaş: Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey
Abdullah Turasan: Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey
Atıl Avcı: Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey

Journal volume & issue: Vol. 15, no. 1

Abstract

Read online

Omalizumab is a recombinant humanized anti-Ig E monoclonal antibody used as the third line treatment of chronic spontaneous urticaria (CSU). We report four patients with severe antihistamine-resistant CSU, who developed angioedema, anaphylaxis and/or flare up of urticaria at different times following omalizumab therapy.

Published in Iranian Journal of Allergy, Asthma and Immunology

ISSN: 1735-1502 (Print); 1735-5249 (Online)
Publisher: Tehran University of Medical Sciences
Country of publisher: Iran, Islamic Republic of
LCC subjects: Medicine
Website: https://ijaai.tums.ac.ir

About the journal

Abstract

Keywords